INTEGRA Pharmaceuticals

Integra Therapeutics is a biotechnology company specializing in the development of next-generation gene writing technologies to treat a wide range of genetic diseases and cancers. The company's proprietary FiCAT (Find and Combined ATtachment) platform combines the precision of CRISPR-Cas9 with the high-capacity integration capabilities of transposases, allowing for the insertion of large gene payloads into the genome with high efficiency and safety. By overcoming the cargo size limitations of viral vectors, Integra Tx aims to provide definitive genomic medicines for complex disorders. The company is currently focused on advancing its pre-clinical pipeline while establishing strategic partnerships to expand the reach of its gene-writing technology.